We thank Dr Naumann for the comments on our randomized controlled trial but do not agree with the interpretation of the data.1 Evidence-based treatment options for functional dyspepsia are very limited.1 In the Functional DyspepsiaTreatment Trial (FDTT), overall the rates for the primary outcome (adequate relief of dyspepsia) were 53% for amitriptyline, 38% for escitalopram, and 40% for placebo, and we accurately reported amitriptyline was borderline superior to placebo.2 We disagree the primary outcome analysis was only driven by the significant difference in favor of amitriptyline over escitalopram; the statistical analysis performed assessed the overall treatment differences.